| 1 |
Lin X, Chen J, Tao C, Luo L, He J, Wang Q. Osthole regulates N6-methyladenosine-modified TGM2 to inhibit the progression of rheumatoid arthritis and associated interstitial lung disease. MedComm (2020) 2023;4:e219. [PMID: 36845072 DOI: 10.1002/mco2.219] [Reference Citation Analysis]
|
| 2 |
Xia J, Zhang L, Gu T, Liu Q, Wang Q. Identification of ferroptosis related markers by integrated bioinformatics analysis and In vitro model experiments in rheumatoid arthritis. BMC Med Genomics 2023;16:18. [PMID: 36717858 DOI: 10.1186/s12920-023-01445-7] [Reference Citation Analysis]
|
| 3 |
Bao L, Ye J, Liu N, Shao Y, Li W, Fan X, Zhao D, Wang H, Chen X. Resveratrol Ameliorates Fibrosis in Rheumatoid Arthritis-Associated Interstitial Lung Disease via the Autophagy-Lysosome Pathway. Molecules 2022;27. [PMID: 36500562 DOI: 10.3390/molecules27238475] [Reference Citation Analysis]
|
| 4 |
Yamakawa H, Toyoda Y, Baba T, Kishaba T, Fukuda T, Takemura T, Kuwano K. Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review. JCM 2022;11:3835. [DOI: 10.3390/jcm11133835] [Reference Citation Analysis]
|
| 5 |
Diesler R, Cottin V. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Rev Respir Med 2022. [PMID: 35695895 DOI: 10.1080/17476348.2022.2089116] [Reference Citation Analysis]
|
| 6 |
Wang Y, Chen T, Yang C, Li Q, Ma M, Xu H, Shi Q, Wang Y, Wang Y, Liang Q. Huangqi Guizhi Wuwu Decoction Improves Arthritis and Pathological Damage of Heart and Lung in TNF-Tg Mice. Front Pharmacol 2022;13:871481. [PMID: 35600883 DOI: 10.3389/fphar.2022.871481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Laria A, Lurati AM, Zizzo G, Zaccara E, Mazzocchi D, Re KA, Marrazza M, Faggioli P, Mazzone A. Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. Front Med 2022;9:837133. [DOI: 10.3389/fmed.2022.837133] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Ahmed S, Handa R. Management of Connective Tissue Disease-related Interstitial Lung Disease. Curr Pulmonol Rep 2022;:1-13. [PMID: 35530438 DOI: 10.1007/s13665-022-00290-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Han M, Zhang N, Mao Y, Huang B, Ren M, Peng Z, Bai Z, Chen L, Liu Y, Wang S, Huang S, Cheng Z. The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients. Front Microbiol 2022;13:839015. [DOI: 10.3389/fmicb.2022.839015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Kishaba T. Current perspective of progressive-fibrosing interstitial lung disease. Respiratory Investigation 2022. [DOI: 10.1016/j.resinv.2022.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Chen N, Diao C, Gao J, Zhao D. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.152004] [Reference Citation Analysis]
|
| 12 |
Huang W, Li X, Huang C, Tang Y, Zhou Q, Chen W. LncRNAs and Rheumatoid Arthritis: From Identifying Mechanisms to Clinical Investigation. Front Immunol 2021;12:807738. [PMID: 35087527 DOI: 10.3389/fimmu.2021.807738] [Reference Citation Analysis]
|
| 13 |
Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev 2022;:103056. [PMID: 35121155 DOI: 10.1016/j.autrev.2022.103056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 14 |
Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY, Lin YJ, Chen HA, Cheng JT, Huang KY, Li KJ, Su YJ, Leong PY, Tsai WC, Lan JL, Chen DY. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore) 2022;101:e28501. [PMID: 35029907 DOI: 10.1097/MD.0000000000028501] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
|
